Pharmacokinetics and Pharmacodynamics of BIWH 3 in Healthy Duffy Positive vs. Duffy Negative Male Volunteers
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to compare the pharmacokinetic and pharmacodynamic effects of escalating dosages of
recombinant human pyro-Glu MCP-1 (BIWH 3) in Duffy positive vs. Duffy negative healthy male
volunteers: plasma levels of monocyte chemotactic protein-1 (MCP-1) and markers of leukocyte,
coagulation, platelet and endothelial activation will be quantified; To examine the safety of
BIWH 3 in this setting